Keros Therapeutics, Inc. (KROS) stock
Close on Nov 12, 2026Market cap $199.86MP/E –Yield –
Keros Therapeutics, Inc. saw revenue fall 83.4% to $40.42M over the twelve months to Sep 30, 2026. Operating income fell 268.1% to -$73.27M, moving the operating margin from 17.9% to -181.3%. Free cash flow was -$48.27M, down 155.4% from a year earlier. At the latest close the market valued the company at $199.86M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $199.86M
- P/E ratio
- –
- Price to sales
- 4.94
- Price to book
- 0.72
- Dividend yield
- –
- Free cash flow yield
- -24.15%
Fundamentals
- Revenue
- $40.42M
- Net income
- -$61.73M
- EPS, diluted
- -$2.80
- Free cash flow
- -$48.27M
- Book value per share
- $13.72
- Diluted shares
- 20M
Trading
- Next earnings
- Mar 3, 2027 (estimated, during market hours)
- Previous close
- $9.54
- Open
- $9.51
- Day's range
- $9.44 – $10.54
- Volume
- 630,138
- Average volume (20 days)
- 189,597
- Index membership
- Russell 2000 (since Jun 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 1.11
- 52-week range
- $8.98 – $22.55
- RSI (14 days)
- 43.0
- Volatility (1 year)
- 51.2%
- Relative volume
- 3.32×
- WACC
- 10.5%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KROS | S&P 500 | Difference | KROS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.2% | -2.7% | −10.5 pts | ||
| 3 months | -10.0% | -1.7% | −8.3 pts | ||
| Year to date | -50.5% | +11.9% | −62.4 pts | ||
| 1 year | -42.3% | +12.0% | −54.3 pts | ||
| 3 years | -65.9% | +78.2% | −144.1 pts | -30.1% | +21.2% |
| 5 years | -83.7% | +73.2% | −156.9 pts | -30.4% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Keros Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- News
- Update
About Keros Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical organization focused on discovering, developing, and commercializing novel protein therapeutics for disorders linked to dysfunctional transforming growth factor-beta (TGF-ß) signaling pathways. Its pipeline centers on engineered ligand traps designed to target tissues such as skeletal muscle, bone, adipose tissue, and blood. The primary product candidate, rinvatercept, targets neuromuscular conditions including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its other key candidate, elritercept, addresses cytopenias such as anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. The company aims to serve patient populations suffering from rare neuromuscular and hematological disorders.
Company profile, executives and historyKeros Therapeutics stock: common questions
What is Keros Therapeutics's stock price?
KROS closed at $10.08 on Nov 12, 2026, up 5.66% on the day. Over the past 52 weeks it traded between $8.98 and $22.55.
What is Keros Therapeutics's market cap?
Keros Therapeutics was worth $199.86M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KROS's P/E ratio?
Keros Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.80), so it has no meaningful P/E ratio.
How much revenue does Keros Therapeutics make?
Keros Therapeutics reported revenue of $40.42M for the twelve months to Sep 30, 2026, down 83.4% from a year earlier.
Does Keros Therapeutics pay a dividend?
No. Keros Therapeutics has not paid a cash dividend over the last twelve months.
When does Keros Therapeutics report earnings next?
Keros Therapeutics is expected to report Q4 FY2026 results on Mar 3, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has KROS stock performed over the past year?
Including dividends, KROS returned -42.3% over the past year, against +12.0% for the S&P 500.
How many KROS shares are sold short?
1M shares were sold short at the latest FINRA report, 11.73% of the float, or 7.1 days of average trading volume.
Who are Keros Therapeutics's competitors?
Companies most similar to Keros Therapeutics by business, industry and size include VRDN, ROIV, VTVT, GOSS, CUE.
See a number that looks wrong?